Allakos Inc.
allakos.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2025 10-Q, filed May 7, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Aug 14, 2025.
10-Q for Q1 FY2025, filed May 7, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops antibody drug candidates targeting immune-cell receptors involved in allergic, inflammatory and proliferative diseases.
10-K for FY2024, filed Mar 12, 2025
How Did They Make Money?
No revenue was reported.
10-K for FY2024, filed Mar 12, 2025
How Were They Changing?
-
May 15, 2025
Concentra completed its acquisition of Allakos
Allakos became a wholly owned subsidiary; shareholders received $0.33 in cash per share, and Nasdaq trading was suspended.
Sources
8-K, filed May 15, 2025
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on May 15, 2025, Merger Sub completed a tender…View ↗
-
Apr 2, 2025
Allakos agreed to be acquired by Concentra
The proposed tender offer and merger provided for $0.33 in cash per share.
Sources
8-K, filed Apr 2, 2025
On April 1, 2025, Allakos Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Concentra…View ↗
Pipeline direction
The older report described lirentelimab and another antibody in development for inflammatory diseases; the latest report says it no longer plans to develop either and is reviewing strategic alternatives.
10-K for FY2021, filed Mar 1, 2022 10-K for FY2024, filed Mar 12, 2025In January 2025, we announced that our product candidate, AK006, did not demonstrate therapeutic activity in patients with Chronic…View ↗
In January 2025, we launched a comprehensive review of strategic alternatives focused on maximizing stockholder value, including, but not…View ↗
We had also been developing lirentelimab (AK002) and, in conjunction with the Phase 2 lirentelimab results in atopic dermatitis and CSU, we…View ↗
Loading...
